Driven to death: Inhibition of farnesylation increases Ras activity in osteosarcoma and promotes growth arrest and cell death

Molecular Cancer Therapeutics

Volumn 9, Issue 5, 2010, Pages 1111-1119

  Geryk Hall, Mandy ^a   Yang, Yanwen ^a   Hughes, Dennis P M ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GGTI 298; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; RAS PROTEIN; TIPIFARNIB;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL DEATH; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; OSTEOSARCOMA; PRIORITY JOURNAL;

ADOLESCENT; ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; CELL CYCLE; CELL DEATH; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG EVALUATION, PRECLINICAL; ENZYME INHIBITORS; FARNESYLTRANSTRANSFERASE; HUMANS; MALE; OSTEOSARCOMA; QUINOLONES; RAS PROTEINS; U937 CELLS; UP-REGULATION;

EID: 77952152971     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-09-0833     Document Type: Article

References (47)

1. Brunner TB, Hahn SM, Gupta AK, Muschel RJ, McKenna WG, Bernhard EJ. Farnesyltransferase inhibitors: an overview of the results of preclinical and clinical investigations. Cancer Res 2003;63:5656-5668
2. Casey PJ. Biochemistry of protein prenylation. J Lipid Res 1992;33:1731-1740
3. Winter-Vann AM, Casey PJ. Post-prenylation-processing enzymes as new targets in oncogenesis. Nat Rev Cancer 2005;5:405-412
4. Adjei AA. Blocking oncogenic Ras signaling for cancer therapy. J Natl Cancer Inst 2001;93:1062-1074
5. Zujewski J, Horak ID, Bol CJ, et al. Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer. J Clin Oncol 2000;18:927.
6. Maurer-Stroh S, Eisenhaber F. Refinement and prediction of protein prenylation motifs. Genome Biol 2005;6:R55.
7. Lancet JE, Karp JE. Farnesyltransferase inhibitors in hematologic malignancies: new horizons in therapy. Blood 2003;102:3880-3889
8. Pan J, Yeung S-CJ. Recent advances in understanding the anti-neoplastic mechanisms of farnesyltransferase inhibitors. Cancer Res 2005;65:9109-9112 (Pubitemid 41507967)
9. Sousa SF, Fernandes PA, Ramos MJ. Unraveling the mechanism of the farnesyltransferase enzyme. J Biol Inorg Chem 2005;10:3-10.
10. Reid TS, Beese LS. Crystal structures of the anticancer clinical candidates R115777 (tipifarnib) and BMS-214662 complexed with protein farnesyltransferase suggest a mechanism of FTI selectivity. Biochemistry 2004;43:6877-6884
11. Khwaja A, Dockrell ME, Hendry BM, Sharpe CC. Prenylation is not necessary for endogenous Ras activation in non-malignant cells. J Cell Biochem 2006;97:412-422 (Pubitemid 43167154)
12. Ashery U, Yizhar O, Rotblat B, Kloog Y. Nonconventional trafficking of Ras associated with Ras signal organization. Traffic 2006;7:119-126 (Pubitemid 44203993)
13. Sherman LS, Ratner N. Immunocytochemical assay for Ras activity. Methods Enzymol 2001:348-355
14. Basso AD, Kirschmeier P, Bishop WR. Thematic review series: lipid posttranslational modifications. Farnesyl transferase inhibitors. J Lipid Res 2006;47:15-31.
15. Shaw NJ, Bishop NJ. Bisphosphonate treatment of bone disease. Arch Dis Child 2005;90:494-499
16. Berthiaume LG. Insider information: how palmitoylation of Ras makes it a signaling double agent. Sci STKE 2002;2002:pe41.
17. Whyte DB, Kirschmeier P, Hockenberry TN, et al. K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors. J Biol Chem 1997;272:14459-14464 (Pubitemid 27232866)
18. Antillon-Klussman F, Garcia-Delgado M, Villa-Elizaga I, Sierrasesumaga L. Mutational activation of ras genes is absent in pediatric osteosarcoma. Cancer Genet Cytogenet 1995;79:49-53.
19. Hughes DP, Thomas DG, Giordano TJ, McDonagh KT, Baker LH. Essential erbB family phosphorylation in osteosarcoma as a target for CI-1033 inhibition. Pediatr Blood Cancer 2006;46:614-623
20. Roux PP, Blenis J. ERK and p38 MAPK-activated protein kinases: a family of protein kinases with diverse biological functions. Microbiol Mol Biol Rev 2004;68:320-344 (Pubitemid 38756868)
21. Junttila MR, Li S-P, Westermarck J. Phosphatase-mediated cross-talk between MAPK signaling pathways in the regulation of cell survival. FASEB J 2008;22:954-965 (Pubitemid 351519953)
22. Bivona TG, Quatela SE, Bodemann BO, et al. PKC regulates a farnesyl-electrostatic switch on K-Ras that promotes its association with Bcl-XL on mitochondria and induces apoptosis. Mol Cell 2006;21:481-493
23. Ninomiya Y, Kato K, Takahashi A, et al. K-Ras and H-Ras activation promote distinct consequences on endometrial cell survival. Cancer Res 2004;64:2759-2765
24. Yang R, Piperdi S, Gorlick R. Activation of the RAF/mitogen-activated protein/extracellular signal-regulated kinase kinase/extracellular signal-regulated kinase pathway mediates apoptosis induced by chelerythrine in osteosarcoma. Clin Cancer Res 2008;14:6396-6404
25. Lisle JW, Choi JY, Horton JA, Allen MJ, Damron TA. Metastatic osteosarcoma gene expression differs in vitro and in vivo. Clin Orthop Relat Res 2008;466:2071-2080
26. Santala P, Larjava H, Nissinen L, Riikonen T, Maatta A, Heino J. Suppressed collagen gene expression and induction of α2β1 integrin-type collagen receptor in tumorigenic derivatives of human osteogenic sarcoma (HOS) cell line. J Biol Chem 1994;269:1276-1283
27. Zhang P, Yang Y, Zweidler-McKay PA, Hughes DPM. Critical role of notch signaling in osteosarcoma invasion and metastasis. Clin Cancer Res 2008;14:2962-2969
28. Tibes R, Qiu Y, Lu Y, et al. Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells. Mol Cancer Ther 2006;5:2512-2521
29. http://www.invitrogen.com/site/us/en/home.html.
30. Raponi M, Belly RT, Karp JE, Lancet JE, Atkins D, Wang Y. Microarray analysis reveals genetic pathways modulated by tipifarnib in acute myeloid leukemia. BMC Cancer 2004;4:56.
31. Yanamandra N, Colaco NM, Parquet NA, et al. Tipifarnib and bortezomib are synergistic and overcome cell adhesion-mediated drug resistance in multiple myeloma and acute myeloid leukemia. Clin Cancer Res 2006;12:591-599
32. Venkatasubbarao K, Choudary A, Freeman JW. Farnesyl transferase inhibitor (R115777)-induced inhibition of STAT3(Tyr705) phosphorylation in human pancreatic cancer cell lines require extracellular signal-regulated kinases. Cancer Res 2005;65:2861-2871
33. Ashar HR, James L, Gray K, et al. Farnesyl transferase inhibitors block the farnesylation of CENP-E and CENP-F and alter the association of CENP-E with the microtubules. J Biol Chem 2000;275:30451-30457
34. Caraglia M, Marra M, Leonetti C, et al. R115777 (Zarnestra)/zoledronic acid (Zometa) cooperation on inhibition of prostate cancer proliferation is paralleled by Erk/Akt inactivation and reduced Bcl-2 and bad phosphorylation. J Cell Physiol 2007;211:533-543
35. 1 arrest by targeting the proteasome. Cancer Res 2006;66:1040-1051
36. Davis AR, Alevy YG, Chellaiah A, Quinn MT, Mohanakumar T. Characterization of HDJ-2, a human 40 kD heat shock protein. Int J Biochem Cell Biol 1998;30:1203-1221
37. Brassard DL, English JM, Malkowski M, Kirschmeier P, Nagabhushan TL, Bishop WR. Inhibitors of farnesyl protein transferase and MEK1,2 induce apoptosis in fibroblasts transformed with farnesylated but not geranylgeranylated H-Ras. Exp Cell Res 2002;273:138-146
38. Wang C-C, Liao Y-P, Mischel PS, Iwamoto KS, Cacalano NA, McBride WH. HDJ-2 as a target for radiosensitization of glioblastoma multiforme cells by the farnesyltransferase inhibitor R115777 and the role of the p53/p21 pathway. Cancer Res 2006;66:6756-6762
39. Shao J, Sheng H, DuBois RN, Beauchamp RD. Oncogenic Ras-mediated cell growth arrest and apoptosis are associated with increased ubiquitin-dependent cyclin D1 degradation. J Biol Chem 2000;275:22916-22924
40. Vos MD, Ellis CA, Elam C, Ulku AS, Taylor BJ, Clark GJ. RASSF2 is a novel K-Ras-specific effector and potential tumor suppressor. J Biol Chem 2003;278:28045-28051
41. Castro ME, del Valle Guijarr M, Moneo V, Carnero A. Cellular senescence induced by p53-ras cooperation is independent of p21waf1 in murine embryo fibroblasts. J Cell Biochem 2004;92:514-524
42. Serrano M, Lin AW, McCurrach ME, Beach D, Lowe SW. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 1997;88:593-602.
43. Gotzmann J, Huber H, Thallinger C, et al. Hepatocytes convert to a fibroblastoid phenotype through the cooperation of TGF-β1 and Ha-Ras: steps towards invasiveness. J Cell Sci 2002;115:1189-1202
44. Zhang Z, Yao R, Li J, et al. Induction of invasive mouse skin carcinomas in transgenic mice with mutations in both H-ras and p53. Mol Cancer Res 2005;3:563-574
45. Raponi M, Lancet JE, Fan H, et al. A 2-gene classifier for predicting response to the farnesyltransferase inhibitor tipifarnib in acute myeloid leukemia. Blood 2008;111:2589-2596
46. Cheng JQ, Ruggeri B, Klein WM, et al. Amplification of AKT2 in human pancreatic cancer cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA. Proc Natl Acad Sci U S A 1996;93:3636-3641
47. Sun J, Qian Y, Hamilton AD, Sebti SM. Both farnesyltransferase and geranylgeranyltransferase I inhibitors are required for inhibition of oncogenic K-Ras prenylation but each alone is sufficient to suppress human tumor growth in nude mouse xenografts. Oncogene 1998;16:1467-1473